Oscar Health (OSCR) Could Be 95% Below Fair Value After Raised 2026 Guidance
Why Oscar Health Stock Is Back in Focus After Guidance Shift
Oscar Health (OSCR) is back on many investors’ watchlists after Q2 2026 earnings beat market expectations and the company raised its full year 2026 revenue and earnings guidance.
See our latest analysis for Oscar Health.
The raised guidance and stronger Q2 earnings have come after a sharp run in Oscar Health’s share price, with a year to date share price return of 84.84% and a three year total shareholder return of 298.70%. This is despite the stock recently pulling back 9.40% over the past 30 days and 9.99% over the past week.
If Oscar Health’s use of AI in healthcare has caught your attention, it can be useful to see what else is out there and review the 43 healthcare AI stocks.
Oscar Health now trades only slightly below the average analyst price target after a very strong run and fresh guidance. Is the market still too cautious, or is it already pricing this rebound fairly as investors look at valuation next?
Most Popular Narrative: 95% Undervalued
According to the most followed Oscar Health narrative, the gap between the last close at $27.67 and a fair value of $583.34 is extremely wide, which sharply contrasts with the relatively tight analyst price target of $28.20.
Suspicious of a value trap, I started digging into the operational engine to find the catch. Instead, the deeper I dug, the more the moat began to show.
Capital Efficiency: The business generates a powerful 27.9% return on invested capital (ROIC), even while operating on a razor thin 4.1% operating margin.
Curious how a health insurer ends up with a triple digit fair value estimate? The narrative leans heavily on compounding growth, rising margins and a punchy profit multiple. Want to see which specific cash flow and return assumptions connect that story to a fair value above $500?
Result: Fair Value of $583.34 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this Oscar Health narrative depends on very optimistic growth and margin assumptions, and any setback in cash generation or regulation could quickly challenge that story.
Find out about the key risks to this Oscar Health narrative.
Another View on Oscar Health’s Valuation
The user narrative leans heavily on a DCF result that puts Oscar Health’s fair value far above the current $27.67 share price. Yet on simpler yardsticks, the stock already looks full. Oscar Health trades on a P/E of 15.5x, which is higher than both the US Insurance industry at 11.6x and its peer group at 12.9x.
At the same time, that 15.5x P/E is below a fair ratio of 23.4x that our regression suggests the market could move toward. For you as an investor, that mix of premium pricing versus today’s peers and a lower P/E than the fair ratio raises a practical question: Is this a margin of safety or a signal that expectations are already demanding?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With both the optimism around Oscar Health and the reservations about its valuation on the table, it makes sense to look at the full picture yourself and move quickly while sentiment is active. To weigh up both sides of the story in one place, review the 3 key rewards and 2 important warning signs.
Looking for more Oscar Health style investment ideas?
If Oscar Health has sharpened your focus, do not stop here. The Simply Wall Street Screener can quickly surface more stocks that fit what you are looking for.
- Target underappreciated quality and let the screener highlight companies that combine strong fundamentals with attractive valuations through the screener containing 21 high quality undiscovered gems.
- Prioritise resilience and use the screener to spot companies that pair solid balance sheets with dependable fundamentals using the solid balance sheet and fundamentals stocks screener (48 results).
- Reduce unpleasant surprises by focusing on companies that our models flag with lower risk profiles through the 83 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com